List of works - Joachim Steinbach

ACNU-based chemotherapy for recurrent glioma in the temozolomide era.

scientific article

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

scientific article published on 4 May 2009

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

scientific article

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

scientific article published in August 2007

Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation

scientific article published on August 2013

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity

scientific article published on 7 January 2016

Gliomatosis cerebri: no evidence for a separate brain tumor entity

scientific article published on 22 October 2015

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition

scientific article published on 29 November 2020

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

scientific article

Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas

scientific article published on 09 July 2020

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

scientific article published on 5 February 2015

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective

scientific article published on 17 April 2013

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.

scientific article

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

scientific article published on 18 March 2015

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

scientific article published on 24 August 2017

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

scientific article published on 13 September 2017

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

scientific article published on 13 September 2017

Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?

scientific article

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

scientific article published in September 2006

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

scientific article

Temozolomide: a milestone in the pharmacotherapy of brain tumors

scientific article

List of works by Joachim Steinbach

ACNU-based chemotherapy for recurrent glioma in the temozolomide era.

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity

Gliomatosis cerebri: no evidence for a separate brain tumor entity

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Temozolomide: a milestone in the pharmacotherapy of brain tumors